1207254-75-8Relevant academic research and scientific papers
INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE
-
Paragraph 00188; 00211; 00232, (2020/05/07)
The present application pertains to methods of using indole-oxadiazole compounds of Formula I to modulate cannabinoid receptor activity: I In particular diseases, disorders or conditions that benefit from modulating cannabinoid receptor activity, such as non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), schizophrenia, bipolar disorder, psychosis, metabolic syndrome, type-2 diabetes, dyslipidaemia, obesity, eating disorders, cardiovascular diseases and disorders, and other conditions as described herein, may be treated. Also included in the present application are certain novel compounds of Formula Ia and pharmaceutical compositions comprising these compounds.
Synthesis of new functionalized 2-alkylsulfanyl-5-(1h-indol-2-yl)-1,3,4- oxadiazole and a facile thio-aza-claisen rearrangement of the s-allyl analog
Ashry, El Sayed H. El,Tamany, El Sayed H. El,Fattah, Mohy El Din Abd El,Aly, Mohamed R. E.,Boraei, Ahmed T. A.
experimental part, p. 462 - 469 (2010/04/23)
The S-alkylated indolyloxadiazoles 2a-l were obtained regioselectively by alkylation of 5-(1 H-indol-2-yl)- 1,3,4-oxadiazole-2(3H)-thione 1, using TEA as acid scavenger. Alkylation of 1 with 1-bromopropane, 1-bromobutane, 1-bromoundecan, in the presence o
